Results 61 to 70 of about 6,337 (198)

Paxlovid use is associated with lower risk of cardiovascular diseases in COVID-19 patients with autoimmune rheumatic diseases: a retrospective cohort study

BMC Medicine
Background Paxlovid has been shown to be effective in reducing mortality and hospitalization rates in patients with coronavirus disease 2019 (COVID-19).
Weijie Wang, Yu-Hsun Wang, Ching-Hua Huang, Tsung-Hsueh Hsieh, Gema Hernández Ibarburu, James Cheng-Chung Wei   +5 more
doaj   +1 more source

Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir—A Literature Review

Advances in Respiratory Medicine
Nirmatrelvir/Ritonavir is an oral treatment for mild to moderate COVID-19 cases with a high risk for a severe course of the disease. For this paper, a comprehensive literature review was performed, leading to a summary of currently available data on ...
Sydney Paltra, Tim O. F. Conrad
doaj   +1 more source

Network medicine and systems pharmacology approaches to predicting adverse drug effects

British Journal of Pharmacology, Volume 183, Issue 8, Page 1627-1639, April 2026.
Identifying and understanding the relationships between drug intake and adverse effects that can occur due to inadvertent molecular interactions between drugs and targets is a difficult task, especially considering the numerous variables that can influence the onset of such events.
Alessio Funari, Giulia Fiscon, Paola Paci   +2 more
wiley   +1 more source

Paxlovid reduces the 28-day mortality of patients with COVID-19: a retrospective cohort study

BMC Infectious Diseases
Purpose In this study, we aim to explore the efficacy of paxlovid on reducing mortality of COVID-19 patients in clinical setting, especially whether paxlovid modifies the risk of death in these severe and critical patients.
Kaican Zong, Li Xu, Chun Luo, Chen Luo, Bin Liu, Jiacheng Chen, Huizi Wu, Zhiqiang Liu, Rongjuan Zhuang, Shuliang Guo   +9 more
doaj   +1 more source

Treating asthma in the time of COVID [PDF]

, 2022
The Precision Interventions for Severe and/or Exacerbation-Prone Asthma clinical trials network is actively assessing novel treatments for severe asthma during the coronavirus disease (COVID-19) pandemic and has needed to adapt to various clinical ...
Carr, Tara F., Fajt, Merritt L., Kraft, Monica, Peden, David B., Phipatanakul, Wanda, Precision Interventions for Severe and/or Exacerbation-Prone Asthma Network Research Group, Szefler, Stanley J., White, Steven R., Zeki, Amir A.   +8 more
core   +2 more sources

Reduced Mortality in COVID‐19 Patients Treated With Inhaled Extracellular Vesicles Expressing CD24

Journal of Extracellular Vesicles, Volume 15, Issue 3, March 2026.
ABSTRACT Background: Severe COVID‐19, and other systemic infections, can trigger hyperinflammation leading to lung injury. EXO‐CD24, an inhaled extracellular vesicle therapy with anti‐inflammatory properties, has shown acute clinical benefit, but long‐term effects on survival remain unknown.
Shiran Shapira, Guy Vishnevsky, Hadas Yaakobi, Gil Shenberg, Mays Motlaq, Eliezer Liberman, Aminadav Kalisky, Gadi Benari, Sotirios Tsiodras, Nimrod Adi, Jan Lötvall, Nadir Arber   +11 more
wiley   +1 more source

Should Paxlovid be prescribed for patients with severe COVID‐19 in the late course of infection? A case report

Medicine Advances, 2023
The infection of the coronavirus disease 2019 (COVID‐19) is often accompanied by pneumonia with both high incidence and mortality. Paxlovid is commonly prescribed in patients with mild and normal pneumonia within 5 days from the symptom onset. Herein, we
Qiang Li, Yibo He, Jin Liu, Xiaozhao Lu, Ziyou Zhou, Yu Kang, Wanying Wu, Jielan Wu, Feng Wang, Yinghao Sun, Wei Wang, Chengyi Hui, Wenting Wei, Miaoyun Wen, Jingjing Chen, Yong Liu   +15 more
doaj   +1 more source

Risks of paxlovid in a heart transplant recipient

The Journal of Heart and Lung Transplantation, 2023
The burden of morbidity and mortality from SARS-CoV-2 infection is especially significant in heart transplant patients who are at higher risk for poor outcomes owing to immunosuppression, blunted response to vaccination, and multiple comorbid conditions.
Kristin Stawiarski, Robin Avery, Sara Strout, Priya Umapathi   +3 more
openaire   +2 more sources

Enhancing the Outcome of Crystallographic Fragment Screening by Choosing the Optimal Protein Crystal Form

Small Science, Volume 6, Issue 3, March 2026.
The selection of the crystal form impacts crystallographic fragment screening (CFS) hit rates. Almost identical CFS campaigns using monoclinic versus orthorhombic crystals of SARS‐CoV‐2 main protease yield hit rates of 3% and 16%. The higher hit rate correlates with larger solvent channels and a less constrained active site in the orthorhombic form ...
Tatjana Barthel, Jan Wollenhaupt, Laila S. Benz, Patrick Reinke, Linlin Zhang, Melanie Oelker, Frank Lennartz, Helena Taberman, Uwe Mueller, Alke Meents, Rolf Hilgenfeld, Manfred S. Weiss   +11 more
wiley   +1 more source

Paxlovid (Nirmatrelvir and Ritonavir) Use in Pregnant and Lactating Woman: Current Evidence and Practice Guidelines—A Scoping Review

Vaccines, 2023
COVID-19 virus, since the detection of the first case in Wuhan in 2019, has caused a worldwide pandemic with significant human, economic and social costs.
Prabal Chourasia, Babu Sriram Maringanti, Morgan Edwards-Fligner, Karthik Gangu, Aniesh Bobba, Abu Baker Sheikh, Rahul Shekhar   +6 more
doaj   +1 more source